Abstract:A series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones were synthesized and their anti-HIV-1 activities were evaluated. Most of these compounds were highly active against wild-type (WT) HIV-1 strain (IIIB) with EC50 values in the range of 0.0038-0.4759 mmol/L. Among those compounds, I-11 had an EC50 value of 3.8 nmol/L and SI (selectivity index) of up to 25,468 indicating excellent activity against WT HIV-1. In vitro anti-HIV-1 activity and resistance profile studies suggested that compounds I-11 and I-12 displayed potential anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and tropism strains (EC(50)s range from 4.3 to 63.6 nmol/L and 18.9-219.3 nmol/L, respectively). On the other hand, it was observed that those two compounds were less effective with EC50 values of 2.77 and 4.87 mmol/L for HIV-1A(17) (K103N + Y181C). The activity against reverse transcriptase (RT) was also evaluated for those compounds. Both I-11 and I-12 obtained sub-micromolar IC50 values showing their potential in RT inhibition. The pharmacokinetics examination in rats indicated that compound I-11 has acceptable pharmacokinetic properties and bioavailability. Preliminary structure-activity relationships and molecular modeling studies were also discussed. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Synthesis and biological evaluation of novel piperidin-4-ol derivatives

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Synthesis and Biological Evaluation of Novel N-[3-(4-phenylpip-erazin-1-yl)-propyl]-carboxamide Derivatives

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

ChemInform Abstract: Synthesis and Biological Evaluation of Novel Piperidin‐4‐ol Derivatives.

Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors

Design, Synthesis, and Biological Activity of Novel 1,4-Disubstituted Piperidine/piperazine Derivatives As CCR5 Antagonist-Based HIV-1 Entry Inhibitors

Design, Synthesis and Preliminary SAR Studies of Novel N-arylmethyl Substituted Piperidine-Linked Aniline Derivatives As Potent HIV-1 NNRTIs.

Design, Synthesis and Biological Activity of Bicyclic Piperidine-Based HIV-1 Inhibitors

Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives.

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Design, Synthesis, and Biological Evaluation of Novel 4‐aminopiperidinyl‐linked 3,5‐disubstituted‐1,2,6‐thiadiazine‐1,1‐dione Derivatives As HIV‐1 NNRTIs

Design, Synthesis, and Biological Evaluation of Piperidinyl-Substituted [1,2,4]Triazolo[1,5-A]pyrimidine Derivatives As Potential Anti-Hiv-1 Agents with Reduced Cytotoxicity.

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Synthesis and Biological Evaluation of a Series of 2-(((5-akly/aryl-1h-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3h)-ones As Potential HIV-1 Inhibitors.

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Synthesis and Biological Evaluation of Novel Hydroxylphenethyl-S-DACOs As High Active Anti-HIV Agents

Piperidine Scaffold As the Novel P2-ligands in Cyclopropyl-Containing HIV-1 Protease Inhibitors: Structure-based Design, Synthesis, Biological Evaluation and Docking Study

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.